Nombre total de rapports de communication : 0
Rapports mensuels de communications au cours des 6 derniers mois : 0
Objets | Détails | Catégories |
---|---|---|
Santé
|
Federal public drug plans, specifically the Non-Insured Health Benefits Program (Health Canada), with respect to decisions and policies that impact reimbursement of therapeutic products for plan beneficiaries
|
Politique ou Programme
|
Santé
|
Food and Drug Regulations with respect to Data Protection under. C.08.004
|
Règlement
|
Santé
|
Food and Drugs Act, specifically with respect to the approval, regulation and life-cycle management of therapeutic products
|
Politique ou Programme
|
Santé
|
Health Canada Health Products & Food Regulatory Modernization
|
Politique ou Programme
|
Développement économique, Industrie, Propriété intellectuelle, Recherche et développement, Sciences et technologies
|
Innovation Agenda led by Innovation, Science and Economic Development Canada, particularly with respect to the life sciences sector
|
Politique ou Programme
|
Santé
|
Medical Devices Regulations under the Food and Drugs Act, specifically with respect to the approval, regulation and life cycle management of medical devices
|
Règlement
|
Santé, Propriété intellectuelle
|
Patent Act as it relates to the regulation of intellectual property for therapeutic products
|
Politique ou Programme
|
Santé, Propriété intellectuelle
|
Patent Act regulations as they relate to the regulation of intellectual property for therapeutic products and the Patented Medicines (Notice of Compliance) Regulations
|
Règlement
|
Santé, Propriété intellectuelle
|
Patent Act with respect to Canada's Access to Medicines Regime (ss. 21.01-21.09)
|
Politique ou Programme
|
Santé
|
Patented Medicine Prices Review Board with respect to regulations of reporting obligations of patentees
|
Politique ou Programme
|
Santé
|
Patented Medicine Prices Review Board with respect to the regulation of pricing of patented drug products
|
Politique ou Programme
|
Santé, Commerce international
|
Proposed and potential policies with respect to current or potential regulation of cross-border trade in pharmaceuticals, including the Export Control List
|
Politique ou Programme
|
Adresse :
200 Whitehall Drive
Markham, ON L3R 0T5
Canada
Numéro de téléphone :
905-946-8999
Lesia Babiak, Chair, Government Affairs Council, Johnson & Johnson Family of Companies
Johnson & Johnson Family of Companies In Canada n'est pas une coalition.
Johnson & Johnson Family of Companies In Canada ne possède aucune filiale qui pourrait être directement intéressée au résultat de l'engagement
Stephen Sampson | Charges publiques occupées
Cabinet d'expert-conseil : Global Public Affairs